Bristol, Santaris to develop RNA drugs in deal with $100M potential

04/17/2013 | Genetic Engineering & Biotechnology News

Bristol-Myers Squibb and Santaris Pharma, which specializes in developing drugs against mRNA and microRNA targets, agreed to collaborate in the discovery and development of drugs using the latter's locked nucleic acid drug technology. Santaris will get research and discovery funding, as well as a $10 million upfront payment from Bristol. The deal also entitles Santaris to as much as $90 million in milestone fees per product plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC